Please use this identifier to cite or link to this item:
Title: Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
Authors: Tan, Chek Kun
Zhuang, Yan
Wahli, Walter
Keywords: Agonists
Peroxisome Proliferator-Activated Receptors
Issue Date: 2017
Source: Tan, C. K., Zhuang, Y., & Wahli, W. (2017). Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome. Expert Opinion on Therapeutic Targets, 21(3), 333-348.
Series/Report no.: Expert Opinion on Therapeutic Targets
Abstract: INTRODUCTION: Peroxisome proliferator-activated receptors (PPARs) are the molecular targets of hypolipidemic and insulin-sensitizing drugs and implicated in a multitude of processes that fine-tune the functions of all organs in vertebrates. As transcription factors they sense endogenous and exogenous lipid signaling molecules and convert these signals into intricate gene responses that impact health and disease. The PPARs act as modulators of cellular, organ, and systemic processes, such as lipid and carbohydrate metabolism, making them valuable for understanding body homeostasis influenced by nutrition and exercise. Areas covered: This review concentrates on synthetic and natural PPAR ligands and how they have helped reveal many aspects of the transcriptional control of complex processes important in health. Expert opinion: The three PPARs have complementary roles in the fine-tuning of most fundamental body functions, especially energy metabolism. Understanding their inter-relatedness using ligands that simultaneously modulate the activity of more than one of these receptors is a major goal. This approach may provide essential knowledge for the development of dual or pan-PPAR agonists or antagonists as potential new health-promoting agents and for nutritional approaches to prevent metabolic diseases.
ISSN: 1472-8222
DOI: 10.1080/14728222.2017.1280467
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Rights: © 2017 Informa UK Limited (trading as Taylor & Francis Group). This is the author created version of a work that has been peer reviewed and accepted for publication by Expert Opinion on Therapeutic Targets, Informa UK Limited. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [ttp://].
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Citations 10

Updated on Sep 17, 2023

Web of ScienceTM
Citations 10

Updated on Sep 17, 2023

Page view(s) 50

Updated on Sep 26, 2023

Download(s) 5

Updated on Sep 26, 2023

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.